Aytu BioPharma, Inc. develops and commercializes prescription medicines focused on complex central nervous system diseases. Its recurring company updates center on EXXUA (gepirone) extended-release tablets, an FDA-approved selective serotonin 5HT1a receptor agonist for major depressive disorder in adults, along with its ADHD products and legacy pediatric portfolio.
News from Aytu also covers operational and financial results, commercial launch activity, retail and Aytu RxConnect patient-access distribution, investor presentations, and product-level clinical and safety information for EXXUA. The company is a Nasdaq-listed specialty pharmaceutical issuer with prescription products sold through commercial distribution channels.
Aytu BioScience reported record fiscal Q4 2020 revenue of $14.9 million, an increase of 82% sequentially and 766% year-over-year, surpassing its entire fiscal 2019 revenue. The company achieved $6.9 million in Consumer Health and $7.9 million in Rx net revenue. Adjusted EBITDA loss was narrowed to ($1.7 million), down from ($3.7 million) in Q4 2019, with $48.3 million in cash on hand. CEO Josh Disbrow highlighted strong revenue performance and positive momentum moving into fiscal 2021, driven by the integration of Aytu and Innovus businesses and upcoming product launches.
Aytu BioScience (NASDAQ:AYTU) will announce its operational results for the fiscal fourth quarter and full year ending June 30, 2020, during a conference call on October 6, 2020, at 4:30 PM ET. Key products include FDA-approved testosterone nasal spray, sleep aid, and other pediatric formulations. The company also distributes COVID-19 rapid tests and is developing Healight technology for respiratory infections. The Form 10-K will be filed post-market on the same day, providing further insights into Aytu’s performance and strategy.
Aytu BioScience (NASDAQ:AYTU) announced the rescheduling of its fourth quarter and FY 2020 conference call, originally set for September 24, 2020, due to additional workload from the Innovus Merger and the Cerecor pediatric portfolio acquisition. The call will discuss record revenue for the fourth quarter and full fiscal year, alongside business progress updates. Aytu's product portfolio includes innovative prescription products targeting significant patient needs, including treatments for low testosterone and pediatric health issues.
Aytu BioScience (NASDAQ: AYTU) will present operational results for the fiscal fourth quarter ending June 30, 2020, on September 24, 2020, at 4:30 p.m. ET. The call will highlight the company’s recent accomplishments and growth strategies. Interested parties can access the live webcast or the archived version on Aytu's website.
Aytu specializes in marketing novel pharmaceutical products, including the only FDA-approved nasal testosterone solution and an oral spray sleep aid. The company also distributes COVID-19 diagnostic tests and is developing a medical device platform for respiratory infections.
Aytu BioScience (NASDAQ:AYTU) has signed a global distribution agreement for the Pinnacle CovID RAD Rapid Antigen Detection Test, designed to deliver COVID-19 results in just fifteen minutes without laboratory equipment. The test, demonstrating 100% specificity and 84.3% sensitivity, is set to scale U.S. manufacturing capacity to 25 million tests per month. This partnership aims to enhance COVID-19 testing efficiency and response times, addressing significant testing bottlenecks as economies begin to reopen.
Aytu BioScience (NASDAQ:AYTU) has partnered with Apollo Med Innovations and Olympus Health and Performance to launch a nationwide mobile COVID-19 testing initiative. This collaboration aims to provide on-demand, compliant COVID-19 testing for companies, utilizing Aytu’s licensed IgG/IgM antibody tests. Apollo will employ sterilization technologies to ensure a safe testing environment. The initiative seeks to address the return-to-work challenge faced by businesses. Company executives highlighted the importance of providing a safe testing solution for employees and customers.
Aytu BioScience (NASDAQ:AYTU) announced the delivery of Healight investigational devices, enabling the near-term initiation of clinical studies for severely ill COVID-19 patients. The devices were developed in collaboration with Sterling Medical Devices and are designed to reduce viral and bacterial loads via ultraviolet A light. Aytu's CEO, Josh Disbrow, emphasized the company's commitment to advancing potential COVID-19 therapies. Positive pre-clinical findings may lead to FDA discussions for human use, targeting both SARS-CoV-2 and broader applications against various pathogens.
Aytu BioScience, Inc. (NASDAQ:AYTU) has announced the delivery of its Healight investigational devices, enabling the near-term initiation of clinical studies on COVID-19 patients. The devices, developed in collaboration with Sterling Medical Devices, aim to assess the safety and efficacy of Healight technology in reducing viral and bacterial loads, including SARS-CoV-2. Pre-clinical data supports its potential use in intensive care settings. Aytu's CEO expressed optimism for Healight's role in combating COVID-19 as the company advances its clinical studies.